GSK · AGEN 10-KMar 16 '26
“Non-cash royalty revenue related to our agreement with GSK increased $7.6 million, to approximately $108.6 million for the year ended December 31, 2025, from $101.0 million for the year ended December 31, 2024, due to increased net sales of GSK's vaccines containing our QS-21 STIMULON adjuvant.”
BMY · AGEN 10-KMar 16 '26
“BMS received an exclusive worldwide license to develop, manufacture, and commercialize AGEN1777 and its derivatives.”
GSK · ZLAB 10-KFeb 26 '26
“license agreement with Tesaro, a company later acquired by GSK, pursuant to which we obtained an exclusive sublicense under certain patents and know-how of GSK (including such patents and know-how licensed from Merck, Sharp & Dohme Corp.”
BMY · ZLAB 10-KFeb 26 '26
“license agreement with Turning Point (a company later acquired by BMS) pursuant to which we obtained an exclusive license to develop and commercialize products containing repotrectinib (AUGTYRO) as an active ingredient in all human therapeutic indications in Greater China.”